Literature DB >> 3720034

Rapid improvement in severe lupus glomerular lesions following intensive plasma exchange associated with immunosuppression.

B R Leaker, G J Becker, J P Dowling, P S Kincaid-Smith.   

Abstract

We report our experience of intensive plasma exchange (PE) in the treatment of 12 females with severe diffuse proliferative lupus nephritis. All had active disease with crescentic lesions demonstrated on biopsy immediately before PE. Nine patients were also treated with high dose steroids, three patients with low dose steroids and most patients also received cytotoxic therapy. Eight of the 12 patients were biopsied immediately after a course of PE. All but one patient (low dose steroid group) showed considerable diminution of histologic activity with resolution of crescentic lesions. Plasma exchange may accelerate such resolution over conventional therapy, prevent subsequent sclerosis and preserve functional renal tissue.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3720034

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  5 in total

Review 1.  [Therapeutic plasma exchange 1996].

Authors:  U Weber; W Riegel; H Köhler
Journal:  Med Klin (Munich)       Date:  1997-10-15

2.  Retrospective study of plasma exchange in patients with idiopathic rapidly progressive glomerulonephritis and vasculitis.

Authors:  A Gianviti; R S Trompeter; T M Barratt; M F Lythgoe; M J Dillon
Journal:  Arch Dis Child       Date:  1996-09       Impact factor: 3.791

Review 3.  The treatment of lupus nephritis.

Authors:  J S Cameron
Journal:  Pediatr Nephrol       Date:  1989-07       Impact factor: 3.714

Review 4.  Lupus nephritis in childhood and adolescence.

Authors:  J S Cameron
Journal:  Pediatr Nephrol       Date:  1994-04       Impact factor: 3.714

Review 5.  Therapeutic apheresis in autoimmune diseases.

Authors:  Rolf Bambauer; Reinhard Latza; Carolin Bambauer; Daniel Burgard; Ralf Schiel
Journal:  Open Access Rheumatol       Date:  2013-11-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.